Health
Retatrutide: The Triple Agonist Still Proving Itself
Retatrutide just posted phase 3 weight loss data hitting three hormone receptors at once. Here is what is confirmed and what remains unproven.
May 27, 2026

Search
60 stories for“market outlook”
Retatrutide just posted phase 3 weight loss data hitting three hormone receptors at once. Here is what is confirmed and what remains unproven.
May 27, 2026

Over-the-counter glucose monitors reached healthy consumers in 2024, but research suggests their readings may not mean what wearers assume.
Jul 22, 2025
